Switch theme
Sign up to access all valuation multiples
Genomictree Inc is a molecular diagnostic company. It is engaged in developing technologies that satisfies the unmet needs of the healthcare market.
2000
n/a
LTM Revenue $17.8M
LTM EBITDA -$8.1M
$183M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Genomictree has a last 12-month revenue of $17.8M and a last 12-month EBITDA of -$8.1M.
In the most recent fiscal year, Genomictree achieved revenue of $1.6M and an EBITDA of -$6.1M.
Genomictree expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Genomictree valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.3M | $1.6M | XXX | XXX | XXX |
| Gross Profit | $17.0M | -$0.2M | XXX | XXX | XXX |
| Gross Margin | 731% | -11% | XXX | XXX | XXX |
| EBITDA | -$4.3M | -$6.1M | XXX | XXX | XXX |
| EBITDA Margin | -183% | -377% | XXX | XXX | XXX |
| Net Profit | -$4.5M | -$6.0M | XXX | XXX | XXX |
| Net Margin | -194% | -371% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Genomictree's stock price is KRW 15110 (or $10).
Genomictree has current market cap of KRW 362B (or $247M), and EV of KRW 268B (or $183M).
See Genomictree trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $183M | $247M | XXX | XXX | XXX | XXX | $-0.30 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Genomictree has market cap of $247M and EV of $183M.
Genomictree's trades at 10.3x LTM EV/Revenue multiple, and -22.5x LTM EBITDA.
Analysts estimate Genomictree's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Genomictree and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $183M | XXX | XXX | XXX |
| EV/Revenue | 113.7x | XXX | XXX | XXX |
| EV/EBITDA | -30.2x | XXX | XXX | XXX |
| P/E | -35.4x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -16.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpGenomictree's NTM/LTM revenue growth is 1%
Genomictree's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged n/a for the same period.
Over next 12 months, Genomictree's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Genomictree's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Genomictree and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -31% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -377% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 42% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -375% | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | n/a | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 88% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 18% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 209% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 617% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Zomedica | XXX | XXX | XXX | XXX | XXX | XXX |
| AnteoTech | XXX | XXX | XXX | XXX | XXX | XXX |
| Proteomics International | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohit | XXX | XXX | XXX | XXX | XXX | XXX |
| Avacta Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Genomictree acquired XXX companies to date.
Last acquisition by Genomictree was XXXXXXXX, XXXXX XXXXX XXXXXX . Genomictree acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Genomictree founded? | Genomictree was founded in 2000. |
| Where is Genomictree headquartered? | Genomictree is headquartered in South Korea. |
| Is Genomictree publicy listed? | Yes, Genomictree is a public company listed on KRX. |
| What is the stock symbol of Genomictree? | Genomictree trades under 228760 ticker. |
| When did Genomictree go public? | Genomictree went public in 2016. |
| Who are competitors of Genomictree? | Similar companies to Genomictree include e.g. Zomedica, AnteoTech, Proteomics International, Biohit. |
| What is the current market cap of Genomictree? | Genomictree's current market cap is $247M |
| What is the current revenue of Genomictree? | Genomictree's last 12-month revenue is $17.8M. |
| What is the current EBITDA of Genomictree? | Genomictree's last 12-month EBITDA is -$8.1M. |
| What is the current EV/Revenue multiple of Genomictree? | Current revenue multiple of Genomictree is 10.3x. |
| What is the current EV/EBITDA multiple of Genomictree? | Current EBITDA multiple of Genomictree is -22.5x. |
| What is the current revenue growth of Genomictree? | Genomictree revenue growth between 2023 and 2024 was -31%. |
| Is Genomictree profitable? | Yes, Genomictree is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
